J. N. Ingle

3.3k citations

43 papers · 2.4k indexed · 1 hit paper · h-index 18

Oncology top 2%
Cancer Research top 1%
Genetics top 5%
Pulmonary and Respiratory Medicine top 5%
Pathology and Forensic Medicine top 2%

Co-authors: Antonio G. Nascimento Camilo Adem Christopher A. Reynolds Vera J. Suman Mitch Dowsett Lester E. Wold Daniel Rayson Alex A. Adjei
Topics: Estrogen and related hormone effects (17 papers)Cancer Treatment and Pharmacology (11 papers)Breast Cancer Treatment Studies (11 papers)
Cited by: Cancer Research Oncology Dermatology
Journals: Journal of Clinical Oncology JNCI Journal of the National Cancer Institute British Journal of Cancer
Partner nations: United States Canada Switzerland

In The Last Decade

J. N. Ingle

41 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

2009 581 citations Mitch Dowsett, Jack Cuzick et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by J. N. Ingle

Since Specialization

Citations

This map shows the geographic impact of J. N. Ingle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. N. Ingle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. N. Ingle more than expected).

Fields of papers citing papers by J. N. Ingle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. N. Ingle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. N. Ingle. The network helps show where J. N. Ingle may publish in the future.

Co-authorship network of co-authors of J. N. Ingle

This figure shows the co-authorship network connecting the top 25 collaborators of J. N. Ingle. A scholar is included among the top collaborators of J. N. Ingle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. N. Ingle. J. N. Ingle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy 2015 ·Cancer Gene Therapy ·Ianko Iankov,Cheyne Kurokawa,Antonino B. D’Assoro,J. N. Ingle,Evidio Domingo‐Musibay,Claire Allen,Catherine M. Crosby,(unknown),Stanley K. Liu,Ileana Aderca,Mark J. Federspiel,Evanthia Galanis	18
2	A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast 2013 ·JNCI Journal of the National Cancer Institute ·Lawrence J. Solin,Robert P. Gray,Frederick L. Baehner,Steven M. Butler,Lorie L. Hughes,Carl Yoshizawa,Diana B. Cherbavaz,S. Shak,David L. Page,G. W. Sledge,Nancy E. Davidson,J. N. Ingle,Edith A. Perez,W. C. Wood,Joseph A. Sparano,S Badve	335
3	Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole 2012 ·Annals of Oncology ·Paul E. Goss,J. N. Ingle,Silvana Martino,Nicholas J. Robert,Hyman B. Muss,Robert B. Livingston,Nancy E. Davidson,Edith A. Perez,Yanin Chávarri-Guerra,David Cameron,Kathleen I. Pritchard,Timothy J. Whelan,L. E. Shepherd,Dongsheng Tu	60
4	TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR- metastatic breast cancer (MBC). 2011 ·Journal of Clinical Oncology ·Ayca Gucalp,SM Tolaney,SJ Isakoff,J. N. Ingle,(unknown),LA Carey,K. L. Blackwell,H. S. Rugo,Lisle Nabell,A. Abbruzzi,José González,D. D. Giri,(unknown),(unknown),Gabriella D’Andrea,(unknown),Pamela Drullinsky,Nancy T. Sklarin,C. Hudis,(unknown)	4
5	Circulating tumor cell (CTC) and CA2729 as predictors of outcome in patients with metastatic breast cancer (MBC) in the prospective TBCRC 005 biomarker study. 2010 ·Journal of Clinical Oncology ·Aditya Bardia,(unknown),(unknown),Lori J. Sokoll,J. N. Ingle,LA Carey,NU Lin,Rachita Nanda,Kumar Visvanathan,Antonio C. Wolff	2
6	Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifenbreakdown → 2009 ·Journal of Clinical Oncology ·Mitch Dowsett,Jack Cuzick,J. N. Ingle,Alan S. Coates,John Forbes,Judith M. Bliss,Marc Buyse,Michael Baum,Aman U. Buzdar,Marco Colleoni,R. Charles Coombes,Claire Snowdon,Michael Gnant,R. Jakesz,Manfred Kaufmann,Francesco Boccardo,Jon Godwin,Christina Davies,Richárd Pető	581
7	Competing Causes of Death From a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast Cancer 2008 ·JNCI Journal of the National Cancer Institute ·(unknown),(unknown),L. E. Shepherd,(unknown),J. N. Ingle,H. B. Muss,Michael Palmer,(unknown),(unknown)	135
8	Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17 2008 ·Annals of Oncology ·J. N. Ingle,Dongsheng Tu,Joseph L. Pater,Hyman B. Muss,Silvana Martino,Nicholas J. Robert,Martine Piccart,M. Castiglione,L. E. Shepherd,Kathleen I. Pritchard,Robert B. Livingston,Nancy E. Davidson,Larry Norton,Edith A. Perez,Jeffrey S. Abrams,David Cameron,Michael Palmer,Paul E. Goss	46
9	American society of clinical oncology 2003 update on the role of biophosphonates and bone health issues in women with breast cancer 2004 ·Breast Diseases A Year Book Quarterly ·Bruce E. Hillner,J. N. Ingle,Rowan T. Chlebowski,Richard L. Theriault	103
10	Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer 2004 ·Journal of Clinical Oncology ·Paul E. Goss,J. N. Ingle,Silvana Martino,Nicholas J. Robert,H. B. Muss,Martine Piccart,Monica Castiglione,Dongsheng Tu,L. E. Shepherd,Joseph L. Pater	63
11	Concordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial N9831 2002 ·JNCI Journal of the National Cancer Institute ·Patrick C. Roche,VJ Suman,Robert B. Jenkins,N E Davidson,Silvana Martino,P. Kaufman,(unknown),Brittany L. Murphy,J. N. Ingle,EA Perez	313
12	Utilization of gene expression profiling to identify markers of disease recurrence in node-negative breast cancer 2001 ·Breast Cancer Research and Treatment ·Patrick C. Roche,(unknown),(unknown),J. N. Ingle,Alexey A. Leontovich,Edith A. Perez,(unknown)	1
13	Metaplastic breast cancer: Prognosis and response to systemic therapy 1999 ·Annals of Oncology ·Daniel Rayson,Alex A. Adjei,Vera J. Suman,Lester E. Wold,J. N. Ingle	176
14	180. A Practical and Affordable Worker Exposure Surveillance System 1999 ·William G. Tankersley,Courtney West,J. N. Ingle,Donna L. Cragle,(unknown),(unknown)	0
15	Uranium Dust Exposure and Lung Cancer Risk in Four Uranium Processing Operations 1995 ·Epidemiology ·(unknown),Janice P. Watkins,J. N. Ingle,(unknown),Charles West,(unknown)	36
16	A Prospective, Randomized Controlled Trial of Megestrol Acetate Among High-Risk Patients with Resected Malignant Melanoma 1989 ·American Journal of Clinical Oncology ·Edward T. Creagan,J. N. Ingle,Allan J. Schutt,Daniel J. Schaid	25
17	Phase II Evaluation of Menogaril in Women with Metastatic Breast Cancer after Failure of First-Line Chemotherapy 1988 ·American Journal of Clinical Oncology ·Harry J. Long,Daniel J. Schaid,Allan J. Schutt,J. N. Ingle,Charles L. Loprinzi,J H Edmonson	7
18	An interim analysis of the randomized surgical adjuvant trial for patients with unfavorable breast cancer 1984 ·International Journal of Radiation OncologyBiologyPhysics ·Alejandra Martínez,David L. Ahmann,(unknown),William D. Payne,Paul Scanlon,R. G. Hahn,J. N. Ingle,J H Edmonson	18
19	Randomized trial of adriamycin (ADR) versus adriamycin + dibromodulcitol (DBD) as second line chemotherapy in women with advanced breast cancer 1982 ·J. N. Ingle,S. Fred Brunk,James E. Krook	2
20	Randomized phase II trial of rubidazone and adriamycin in women with advanced breast cancer. 1980 ·PubMed ·J. N. Ingle,David L. Ahmann,Judith R. OʼFallon,Harry F. Bisel,(unknown),Larry K. Kvols,Enrico Giuliani	9

About J. N. Ingle

J. N. Ingle is a scholar working on Cancer Research, Oncology and Genetics, having authored 43 papers that have together received 2.4k indexed citations. Recurring topics across this work include Estrogen and related hormone effects (17 papers), Cancer Treatment and Pharmacology (11 papers) and Breast Cancer Treatment Studies (11 papers). The work is most often cited by research in Cancer Research (1.2k citations), Oncology (1.4k citations) and Dermatology (243 citations). J. N. Ingle has collaborated with scholars based in United States, Canada and Switzerland. Frequent co-authors include Antonio G. Nascimento, Camilo Adem, Christopher A. Reynolds, Vera J. Suman, Mitch Dowsett, Lester E. Wold, Daniel Rayson, Alex A. Adjei, L. E. Shepherd and N E Davidson. Their work appears in journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact